Description: Effective chemotherapy-induced neutropenia treatment with Releuko®. Learn how this solution can help manage low white blood cell counts, reducing infection risks.
Releuko (filgrastim-ayow) injection is biosimilar to Neupogen® (filgrastim) and made entirely in the United States. 1 Filgrastim is a recombinant granulocyte colony stimulating factor (rG-CSF). It promotes neutrophil production in appropriate patients.
Releuko is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Releuko® clinical comparability includes data from 112 subjects evaluated in 2 PK/PD studies and 134 subjects in 1 immunogenicity/safety study: